Phio Pharmaceuticals (PHIO) AI Stock Analysis

• Market Cap: $7.36M
• Dividend Yield: N/A
• Average Volume (3M): 102.97K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.10
• Revenue Growth: N/A
• EPS Growth: 81.71%
• Country: US
• Employees: 8
• Sector: Healthcare
• Sector Strength: 74
• Industry: Biotechnology
• EPS (TTM): -10.33
• Shares Outstanding: 4,778,154
• 10 Day Avg. Volume: 81,543
• 30 Day Avg. Volume: 102,969
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -0.20
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $4.00
• Price Target Upside: 159.74% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Phio Pharmaceuticals faces significant financial hurdles, characterized by a lack of revenue and persistent losses. The technical indicators suggest a bearish trend, and the valuation highlights the absence of profitability. The strategic board appointment offers some positive outlook, but the company's immediate challenges overshadow this potential.

Positive Factors

Clinical Trial Success

Two patients with CSCC who completed treatment with PH-762 showed a complete response (100% tumor clearance).

Immunotherapy Potential

INTASYL technology enables the creation and precision delivery of uniquely modified small interfering RNA, showing potential for multiple immunotherapeutic applications.

Safety and Tolerability

PH-762 intratumoral (IT) injection has been well-tolerated in all enrolled patients, with no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects.

Negative Factors

Underappreciated Potential

The potential for the PH-762 Phase 1b study to generate data flow that could be positive catalysts through 2025 is underappreciated.

Phio Pharmaceuticals Business Overview & Revenue Model

Company Description

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

How the Company Makes Money

Phio Pharmaceuticals generates revenue through strategic partnerships, research collaborations, and licensing agreements related to its RNAi technology platform. The company aims to out-license its proprietary sd-rxRNA technology to larger pharmaceutical or biotechnology companies, which can incorporate these therapies into their own cancer treatment pipelines. Additionally, Phio may receive milestone payments and royalties from these partnerships based on the successful development and commercialization of its therapeutics. The company might also secure funding through grants and government programs aimed at supporting innovative cancer research.

Phio Pharmaceuticals Financial Statement Overview

Summary

Phio Pharmaceuticals is struggling financially with ongoing losses and negative cash flows. Despite a solid equity base and cash reserves, the lack of revenue growth and profitability poses significant challenges. The company needs to improve its revenue generation and cost management to enhance financial stability and investor confidence.

Income Statement

Phio Pharmaceuticals shows a consistent pattern of negative net income and EBIT over the years, with no significant revenue generation. The TTM period shows a small gross profit margin improvement, but still negative, indicating ongoing challenges in covering costs with current revenue levels. The company lacks revenue growth, highlighting difficulties in its business model or market conditions.

Balance Sheet

The balance sheet reflects a strong equity position relative to liabilities, as indicated by a high equity ratio. However, the absence of debt and reliance on equity for financing may suggest limited leverage for growth. The company's ability to maintain a healthy cash balance is a positive aspect, although overall asset efficiency is questionable given the financial performance.

Cash Flow

The cash flow statement indicates consistently negative operating and free cash flows, showing that the company is not generating sufficient internal cash to cover operational needs. This, combined with reliance on external financing, points to challenges in sustainable cash flow management. The lack of improvement in cash flow metrics raises concerns about long-term viability.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
30.00K	0.00	0.00	0.00	0.00	21.00K
	Gross Profit
-48.00K	-6.33M	-193.00K	-192.00K	-183.00K	16.70K
	EBIT
-7.49M	-10.82M	-11.46M	-13.51M	-8.79M	-8.99M
	EBITDA
-7.29M	-10.64M	-11.29M	-13.09M	-8.72M	-8.92M
	Net Income Common Stockholders
-7.42M	-10.83M	-11.30M	-13.21M	-8.79M	-8.84M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
357.00K	8.49M	11.78M	24.06M	14.24M	6.93M
	Total Assets
1.33M	9.36M	12.81M	25.17M	15.74M	8.04M
	Total Debt
1.02M	35.00K	305.00K	295.00K	642.00K	518.00K
	Net Debt
666.00K	-8.46M	-11.48M	-23.76M	-13.60M	-6.42M
	Total Liabilities
3.10M	1.63M	1.98M	3.24M	2.72M	2.29M
	Stockholders Equity
-1.78M	7.73M	10.84M	21.93M	13.02M	5.75M
Cash Flow		Free Cash Flow
-7.52M	-10.75M	-12.25M	-11.91M	-8.82M	-8.72M
	Operating Cash Flow
-7.52M	-10.75M	-12.13M	-11.86M	-8.80M	-8.64M
	Investing Cash Flow
0.00	-5.00K	-121.00K	-51.00K	-19.00K	-72.00K
	Financing Cash Flow
5.04M	7.41M	-26.00K	21.72M	16.13M	772.00K

Phio Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.54
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PHIO, the sentiment is Positive. The current price of 1.54 is above the 20-day moving average (MA) of 1.27, above the 50-day MA of 1.52, and below the 200-day MA of 2.77, indicating a neutral trend. The MACD of -0.10 indicates Negative momentum. The RSI at 39.67 is Neutral, neither overbought nor oversold. The STOCH value of 25.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PHIO.

Phio Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	48 Neutral	$6.36B	1.24	-44.94%	2.70%	18.33%	1.47%
OTRK	39 Underperform	$6.36M	―	-782.98%	―	-4.05%	89.52%
PHIO	28 Underperform	$7.36M	―	-114.83%	―	―	81.71%
GTBP	26 Underperform	$5.73M	―	-453.39%	―	―	-26.02%
DRMA	25 Underperform	$4.80M	―	-310.44%	―	―	75.68%
AEON	24 Underperform	$4.51M	<0.01	13.29%	―	―	-261.69%

Phio Pharmaceuticals Corporate Events

Phio Pharmaceuticals Appoints David Deming to Board

Phio Pharmaceuticals Corp. announced the appointment of David H. Deming to its Board of Directors, effective February 19, 2025. Mr. Deming, with over 30 years of experience in investment banking and asset management, will serve on the Board’s Nominating Committee. This strategic appointment is expected to bolster Phio’s capabilities as it advances its gene silencing technology in the biopharma sector, particularly in immuno-oncology therapeutics.